Kamat - Figure 31
MCNA in BCG-unresponsive Patients
FIG. 31: Among the patients in the Phase 2 MCNA study the BCG-unresponsive patients had a better response (disease-free survival 34.8%) than the overall population (25%).[27,28] This was unexpected, because BCG-unresponsive patients have generally been considered to have a worse response to therapy. The reason for the better response in the BCG-unresponsive subgroup remains to be elucidated and could be related to immune challenge mechanisms, but in any case this represents another report recognizing this subgroup of patients.
References
Li R, Amrhein J, Cohen A, et al. Efficacy of Mycobacterium phlei cell wall-nucleic acid complex (MCNA) in BCG-unresponsive patients. Bladder Cancer. 2017;3:65–71 https://dx.doi.org/10.3233%2FBLC-160084
Morales A, Herr H, Steinberg G, et al. Efficacy and safety of MCNA in patients with nonmuscle invasive bladder cancer at high risk for recurrence and progression after failed treatment with bacillus Calmette-Guérin. J Urol. 2015;193:1135−43 http://dx.doi.org/10.1016/j.juro.2014.09.109
